Results 121 to 130 of about 138,886 (226)

Travelling with visceral leishmaniasis [PDF]

Clinical Microbiology and Infection, 2020
A A, Ahmed, W, Li, R A, Livingston
openaire   +2 more sources

Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis.

, 2006
BACKGROUND: Leishmania species that occur within different geographical areas may cause different clinical manifestations, virulence and drug sensitivity. Patients/Methods.
Lockwood, D, Scarisbrick, JJ, Moody, A, Vega-López, F, Chiodini, PL, Watson, J, Armstrong, M, Bryceson, A   +7 more
core   +1 more source

Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.

, 2007
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia.
Mercedes Del Pilar Mahecha, Juan Carlos Vega, Del Pilar Mahecha, Mercedes, Vega, Juan Carlos, Reithinger, Richard, Ángela Rocío Baron, Rafael Montaña, Montaña, Rafael, Sanchez, Boris Fernando, Montero, Luz Mery, Baron, Angela Rocío, Boris Fernando Sanchez, Bladimir Dueñes, Richard Reithinger, Luz Mery Montero, Dueñes, Bladimir, Sánchez Polania, Boris Fernando, Rozo Montaña, Rafael Augusto   +17 more
core   +1 more source

The effects of host-vector relationships and density dependence on the epidemiology of visceral leishmaniasis [PDF]

In Latin America, visceral leishmaniasis (VL) is caused by infection with Leishmania infantum, an endemic but lethal parasite transmitted by Lutzomyia longipalpis sandflies.
Dilger, Erin
core  

Immunity and immunosuppression in experimental visceral leishmaniasis

Brazilian Journal of Medical and Biological Research, 2004
Leishmaniasis is a disease caused by protozoa of the genus Leishmania, and visceral leishmaniasis is a form in which the inner organs are affected. Since knowledge about immunity in experimental visceral leishmaniasis is poor, we present here a review on
Goto H., Lindoso J.A.L.
doaj  

Miltefosine: issues to be addressed in the future.

, 2006
Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice ...
Berman, J, Croft, S, Sundar, S, Bryceson, ADM, Bryceson, A. D. M., Karbwang, J, Sindermann, H, Berman, J., Engel, J., Urbina, J. A., Gutteridge, W, Engel, J, Croft, S., Gutteridge, W., Karbwang, J., Soto, J., Soto, J, Urbina, JA, Sindermann, H., Sundar, S.   +19 more
core   +1 more source

Visceral leishmaniasis and AIDS [PDF]

Nature, 1994
M, de Gorgolas, M A, Miles
openaire   +2 more sources

Dyserythropoiesis in visceral leishmaniasis [PDF]

American Journal of Hematology, 2010
openaire   +2 more sources

Visceral leishmaniasis

Tropical Parasitology, 2015
openaire   +3 more sources

Visceral leishmaniasis in a multiple sclerosis patient: a rare complication of fingolimod-induced lymphopenia. [PDF]

Rev Esp Quimioter
García-Alabarce A, Cornejo-Calvo E, de Salazar-González A, Guirao-Arrabal E.   +3 more
europepmc   +1 more source